The Center for Alternatives to Animal Testing is an academic center affiliated with the Division of Toxicological Sciences in the Department of Environmental Health Sciences of the Johns Hopkins University Bloomberg School of Public Health.
Text Size:
TestSmart Endocrine Disruptors
February 25-26
Hyatt Fair Lakes Hotel
12777 Fair Lakes Circle
Fairfax, VA
Program Committee:
Richard A. Becker, American Chemistry Council
Alan M. Goldberg, Johns Hopkins University
Pamela J. Lein, Johns Hopkins University
Ellen K. Silbergeld, Johns Hopkins University
Gary Timm, US Environmental Protection Agency
James D. Yager, Johns Hopkins University
Proceedings for TestSmart -- Endocrine Disruptors
WHERE ARE WE TODAY?
- Endocrine Disruption: State of the Science
James D. Yager, Johns Hopkins University - EPA Update on Validation and Standardization
Gary Timm, United States Environmental Protection Agency - OECD Update on Validation and Standardization
Herman Koeter, OECD - Industry's Perspective on Screening and Testing of Hormonally Active Agents
Richard A. Becker, American Chemistry Council - Endocrine Disruption: Perspective of the Animal Protection Community
Martin L. Stephens, Humane Society of the United States
REDUCTION
- Breakout Session I - Thoughtful Science
Chair: L. Earl Gray, Jr., United States Environmental Protection AgencyFocus: What methods exist for increasing the quantity and quality of data obtained from whole animal testing? In particular, can additional endpoints be included in whole animal tests?
- Breakout Session II: Interspecies Extrapolation
Chair: John McLachlan, Tulane and Xavier UniversitiesFocus: What are the critical mechanistic similarities and differences between wildlife species of concern, mammalian models and humans? Do we have to test multiple species?
- Breakout Session III: In Vivo Imaging Techniques
Chair: Pamela Reilly Contag, Xenogen CorporationFocus: Are there in vivo imaging techniques currently available that can be brought to bear on the issue of endocrine disruptor screening and testing? For which endpoints will these techniques be useful?
- Evening Poster Session
Topic: Mechanisms of endocrine disruption and novel methods for endocrine disruptor screening and testing
REPLACEMENT
- Breakout Session IV: In Vitro Assays For Disruption Of The Thyroid Hormone System
Chair: Thomas Zoeller, University of MassachusettsFocus: Are there existing in vitro assays that can be used to screen and detect chemicals that disrupt the thyroid hormone system? Which endpoints would be amenable for developing in vitro assays for this purpose? Are any of these adaptable to high throughput screening?
- Breakout Session V: In Vitro Assays For Non-Receptor Mediated Endpoints
Chair: Robert Brueggemeier, Ohio State University Health SciencesFocus: What endpoints other than receptor binding can be assessed using existing in vitro assays? How relevant are these in vitro assays to ED screening and testing? What is the potential for these to replace animal tests recommended by EDSTAC? Are any of these adaptable to high throughput screening?
- Breakout Session VI: Application Of Genomics And Proteomics To Endocrine Disruptor Screening And Testing
Chair: Bernard Robaire, McGill UniversityFocus: Which endpoints of concern are particularly amenable to these technologies? What is the best approach for determining sensitivity and specificity, and properly validating and standardizing these technologies? What is the best approach for establishing relevance of these technologies to endpoints/effects of known biological significance? To this end, what is the feasibility of collecting tissues from ongoing endocrine screening and testing programs for use in genomics and proteomic studies?
General Discussion and Summary
Ellen K. Silbergeld, Johns Hopkins University
Pamela Lein, Johns Hopkins University